How often should levetiracetam (Keppra) levels be checked?

Routine Levetiracetam Level Monitoring is Not Necessary

Levetiracetam (Keppra) levels do not require routine monitoring in most patients, as therapeutic drug monitoring has not been shown to correlate with efficacy or toxicity. 1

General Approach to Monitoring

Standard Practice

• No routine therapeutic drug monitoring is recommended for levetiracetam in the general epilepsy population 1
• The drug has linear, predictable pharmacokinetics with minimal protein binding (<10%) and no significant drug-drug interactions through hepatic metabolism 2, 3
• Steady-state concentrations are achieved within 24-48 hours of dosing 2, 3

When to Consider Checking Levels

Individual therapeutic ranges may be useful in specific populations where pharmacokinetics are altered: 4

Special Populations Requiring Consideration:

• Elderly patients (>65 years): Clearance decreased by approximately 50% compared to adults due to reduced renal function 2, 4
• Pediatric patients: Clearance increased by 30-40% compared to adults; body weight significantly correlates with clearance 2, 4
• Neonates: Highly variable pharmacokinetics with linear decline in clearance 2
• Critically ill patients: May have augmented clearance requiring higher doses 4
• Pregnant patients: Levels decline progressively during pregnancy due to increased glomerular filtration rate; postpartum levels normalize rapidly 4, 5
• Renal impairment: Clearance reduced by 40% (mild), 50% (moderate), and 60% (severe renal dysfunction) 2
• End-stage renal disease on hemodialysis: Approximately 50% of levetiracetam is removed during standard 4-hour dialysis 2, 6

Monitoring for Specific Clinical Scenarios

Renal Dysfunction

• Check levels if breakthrough seizures occur in patients with creatinine clearance <70 mL/min 2
• Dose adjustments based on creatinine clearance are more important than routine level monitoring 2
• For hemodialysis patients, supplemental dosing after dialysis is recommended rather than routine level checks 2, 6

Pregnancy Management

• Consider checking levels each trimester if seizure control changes, as clearance increases throughout pregnancy 4, 5
• Postpartum dose adjustments should follow empiric tapering protocols (at days 1,7, and 21) rather than routine level monitoring 5

Suspected Non-Adherence or Treatment Failure

• Check levels when seizures worsen to distinguish between inadequate dosing, non-compliance, or true treatment failure 4
• Levels may help establish an individual therapeutic range for patients who achieve seizure control 4, 7

Drug Interactions

• Consider checking levels when enzyme-inducing antiepileptics are added or removed (phenytoin, carbamazepine, oxcarbazepine), as these can decrease levetiracetam concentrations by 20-30% 8
• Valproic acid and lamotrigine do not significantly affect levetiracetam levels 8

Reference Range Considerations

Therapeutic Range

• The proposed therapeutic reference range is 10-40 mg/L (μg/mL) 7
• However, seizure control and adverse effects occur at levels below, within, and above this range, limiting its clinical utility 4, 7
• No positive correlation exists between specific levels and efficacy or toxicity 4

Complete Blood Count Monitoring

• Monitor CBC periodically rather than drug levels, as this is the recommended laboratory monitoring for levetiracetam 1

Common Pitfalls

• Avoid routine level monitoring in stable patients, as it adds cost without proven benefit 4
• Do not assume levels predict seizure control—clinical response is more important than achieving a specific serum concentration 4, 7
• Remember that levetiracetam clearance is primarily renal, not hepatic, so hepatic dysfunction does not require dose adjustment 2, 3
• In critically ill patients, standard dosing may be insufficient due to augmented renal clearance; consider higher doses based on clinical response rather than routine levels 4